ArticleJournal of market access & health policy2017
Analysis of health economics assessment reports for pharmaceuticals in France - understanding the underlying philosophy of CEESP assessment.
Article in Journal of market access & health policy, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- Procedural Theatre: EU-HTA Between Ritual and Purpose-Why the Buyer's Audit Has Outgrown the Transaction.Journal of market access & health policy · 2026Article
- A Review of Current Approaches to Evaluating and Reimbursing New Medicines in a Subset of OECD Countries.Applied health economics and health policy · 2024Review
- Do France, Germany, and Italy agree on the added therapeutic value of medicines?International journal of technology assessment in health care · 2023Article
- Cost-Utility Analysis of Nivolumab in Adjuvant Treatment of Melanoma in France.Dermatology and therapy · 2020Article
- Economic evaluation of biosimilars for reimbursement purposes - what, when, how?Journal of market access & health policy · 2020Article
- Timely, consistent, transparent assessment of market access evidence: implementing tools based on the HTA Core Model® in a pharmaceutical company.International journal of technology assessment in health care · 2019Article
- Comparison of health technology assessment for new medicines in France and England: an example based on ixazomib for patients with relapsed or refractory multiple myeloma.Journal of market access & health policy · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.